Showing 62,181 - 62,200 results of 63,782 for search '(( 09 ((0 decrease) OR (a decrease)) ) OR ( 20 ((mean decrease) OR (we decrease)) ))', query time: 1.66s Refine Results
  1. 62181
  2. 62182

    Datasheet1_Analysis identifying minimal governing parameters for clinically accurate in silico fractional flow reserve.pdf by Cyrus Tanade (14225525)

    Published 2022
    “…FFRinvasive, FFRstreamlined vs. FFRinvasive had decreased correlation (r=0.64, p<0.001), improved agreement (mean difference: 0.01±0.08), and comparable diagnostic performance (sensitivity: 79.0%, specificity: 90.3%, PPV: 83.3%, NPV: 87.5%, AUC: 0.90).…”
  3. 62183

    MicroRNA-379 (miR-379) expression in normal, fibroadenoma and malignant breast tissues. by Sonja Khan (432687)

    Published 2013
    “…<p>RQ-PCR of miR-379 revealed significantly decreased levels of expression in breast cancer n=100 (Mean(SEM) 1.9 (0.09) Log<sub>10</sub> Relative Quantity) compared to normal tissue n=30 (2.6 (0.16) Log<sub>10</sub> RQ, p<0.01).…”
  4. 62184

    Table 1_Long-term oyster shell powder applications increase crop yields and control soil acidity and cadmium in red soil drylands.docx by Hao Li (31608)

    Published 2025
    “…In addition, exchangeable aluminum contents decreased by 5.05%-26.09%, 23.23%-46.27%, and 39.73%-66.97%. …”
  5. 62185

    DataSheet_1_Physiological Basis of Genotypic Response to Management in Dryland Wheat.docx by Amanda de Oliveira Silva (8281134)

    Published 2020
    “…The goals of this study were to (i) determine whether the SM adopted is adequate to reach achievable yields by farmers in the region and (ii) identify differences in responsiveness to IM among a range of modern genotypes. Across all sites-years and genotypes, the IM increased yield by 0.9 Mg ha<sup>-1</sup>, outyielding the SM system even in the lowest yielding conditions. …”
  6. 62186

    Supplementary Material for: Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 st... by Finn R.S. (4148578)

    Published 2024
    “…For pain, both arms had similar risk of deterioration (HR, 0.78; 95% CI, 0.56-1.09). At cycle 4 and 6, patients in the tislelizumab arm maintained in EQ-5D-5L visual analog scale, whereas scores decreased for the patients in the sorafenib arm. …”
  7. 62187
  8. 62188
  9. 62189
  10. 62190
  11. 62191
  12. 62192
  13. 62193
  14. 62194
  15. 62195
  16. 62196
  17. 62197
  18. 62198
  19. 62199
  20. 62200